Search papers, labs, and topics across Lattice.
The paper addresses the problem of pathological outliers distorting site-effect estimation in diffusion MRI (dMRI) data harmonization using ComBat. They demonstrate that including patients with neurological disorders in ComBat harmonization induces significant distortions and evaluate multiple outlier rejection methods. The authors propose Robust-ComBat, which uses a simple MLP for robust outlier compensation, and show that it consistently outperforms conventional ComBat variants in both control and real multi-site cohorts with high proportions of neurological disorders.
Standard ComBat harmonization methods fall apart when applied to dMRI data containing neurological disorders, but a simple MLP-based outlier compensation fixes the problem.
Harmonization methods such as ComBat and its variants are widely used to mitigate diffusion MRI (dMRI) site-specific biases. However, ComBat assumes that subject distributions exhibit a Gaussian profile. In practice, patients with neurological disorders often present diffusion metrics that deviate markedly from those of healthy controls, introducing pathological outliers that distort site-effect estimation. This problem is particularly challenging in clinical practice as most patients undergoing brain imaging have an underlying and yet undiagnosed condition, making it difficult to exclude them from harmonization cohorts, as their scans were precisely prescribed to establish a diagnosis. In this paper, we show that harmonizing data to a normative reference population with ComBat while including pathological cases induces significant distortions. Across 7 neurological conditions, we evaluated 10 outlier rejection methods with 4 ComBat variants over a wide range of scenarios, revealing that many filtering strategies fail in the presence of pathology. In contrast, a simple MLP provides robust outlier compensation enabling reliable harmonization while preserving disease-related signal. Experiments on both control and real multi-site cohorts, comprising up to 80% of subjects with neurological disorders, demonstrate that Robust-ComBat consistently outperforms conventional statistical baselines with lower harmonization error across all ComBat variants.
